Although high Lp-PLA2 activity and mass were associated with increased risk of CHD and stroke, pharmacological lowering of Lp-PLA2 activity with darapladib does not significantly reduce cardiovascular (including stroke) events in patients who have experienced an ACS or with stable coronary heart disease [11, 30]. This evidence concerns the gene PLA2G7 and stroke disorder.